ESOT J2.0

TRANSPLANTATION LEARNING JOURNEY
Prague, 15-17 November 2020

Consensus workshops
Mentoring and learning sessions
Scientific sessions

www.esot.org
ESOT is building on the strengths of the TLJ 2018 experience (cross-fertilization among different topic and field experts) to launch a completely new project, TLJ 2.0. The concept underlying TLJ is LEARNING: we must recognize that learning never stops and that emerging stars, expert professionals and opinion leaders all need to keep learning to stay on top of their discipline. TLJ 2.0 aims at providing value and producing concrete outcomes for all three of the above categories of transplantation professionals.

The meeting now has a completely new structure, that extends the event beyond the face-to-face experience by introducing preparatory pre-meeting work to support consensus workgroups, and pre- and post-meeting interaction and discussion among all participants.

Led by ESOT Sections, the TLJ 2.0 programme targets all audiences by including consensus workgroups, small mentoring sessions and keynote lectures, all connected seamlessly by ESOT usual innovative approach to meetings.

Workgroups will develop a series of consensus papers aimed for publications in Transplant International and further dissemination and interaction will be achieved by interactive materials hosted on Transplant Live, the ESOT e-learning platform.

Patients are welcome to attend and will be invited to contribute.

TLJ 2.0 is a comprehensive experience that will involve participants throughout the year and create a discussion that will continue beyond the face-to-face meeting.

Discussion Boards on Transplant Live will enable consensus work and allow for extended participation of ESOT members. Look out for the announcement when the boards will be open.
Topics will be discussed in Consensus Workshops (WS) on Day 1 and presented and shared in plenary for open discussion during Day 2.

Topics have been selected based on an extensive consultation process among ESOT Sections & Committees.

**New surrogate end points in transplantation**
Given the improved survival of both patients and organs in the modern era we need validated surrogate end points of efficacy if clinical research in transplantation is to progress

Responsible Leaders: Maarten Naesens, Stefan Schneeberger

**CMV infection and disease – the impact on transplanted patients**
What is the optimal management of CMV in transplant recipients

Responsible Leader: Paolo Grossi

**Cancer in pre-and post-transplant recipients**
What is the approach to the risks of transplanting patients with a history of cancer and also how do we best approach the treatment of solid organ tumours in transplant recipients

Responsible Leader: Umberto Maggiore

**Normothermic regional perfusion (NRP) in donation after circulatory death (DCD)**
How will the new techniques and technology in the field of organ preservation and regeneration change the field of transplantation

Responsible Leader: Ina Jochmans
Expanding the recipient pool - reconsidering "no-gos"?
With transplantation being the gold standard treatment for organ failure are we denying this treatment to patients who would otherwise benefit.
What is the evidence base to deny transplantation on the basis of:
• Obesity • Frailty • HIV and / or HCV positive recipients

Responsible Leader: Sarwa D. Murad

Transplanting Across Immunological Barriers
Despite a marked increase in the number of living-donor allografts (LDAs) transplanted annually, many potential recipients with otherwise suitable donors are relegated to the ever-expanding deceased-donor waiting list because of preformed human leukocyte antigen (HLA) antibodies. These are acquired via pregnancy, transfusion, and/or prior transplant. The presence of these anti-HLA antibodies in the potential recipient’s blood is called HLA sensitization. If not adequately suppressed, the presence of such antibodies is likely to result in antibody-mediated rejection (ABMR) and early graft loss. To date, there is no standard protocol for desensitization or post-transplant management to mitigate the risk of ABMR following desensitization that is effective in every patient with an anti-HLA antibody. The development of a more reliable, safe, and cost-effective approach would offer a major benefit.

Responsible Leader: Nizam Mamode
ONE DAY SCIENTIFIC SESSIONS

The last day of TLJ 2.0 will be organized with full day scientific sessions focused on specific topics and organized by ESOT Sections & Committees.

As of March 2020, we are considering the following topics:

- **Combined transplantation**
  Organized by EKITA

- **Heart and Lung**
  - Biventricular heart failure (VADs and artificial hearts)
  - Ex Vivo Lung Perfusion (EVLP)
  Organized by ECTTA

More exciting sessions to be confirmed soon.

LEARNING WORKSTREAM - DAY 1, 2 AND 3

- **DCD, living donors and patients self-management**

  A full stream of mutual understanding and learning dedicated to Transplant Donor Coordinators, Allied Healthcare Professionals, Ethical, Legal and Psychosocial Aspects of Organ Transplantation and the European Transplant Patient Organization (ETPO) will run in parallel to the above mentioned activities.

  In collaboration with ETPO Alliance - European Transplant Patient Organization Alliance

  The Digital Outpatients Awards will be announced during this session.

  This is part of the educational initiative for patients ESOT has launched in 2019.
TARGET AUDIENCE

WHO SHOULD ATTEND?

The target audience for TLJ 2.0 includes all fields involved in health care and research with an affiliation in transplantation. This includes but is not limited to:

- Transplant surgeons
- Physicians from all fields with an involvement in transplantation
- Coordinators, Nurses
- Researchers in emerging fields (stem cells, artificial organs, tissue and organ regeneration)
- General surgeons and clinicians with an interest in transplantation
- Transplant scientists
- Nutrition and rehabilitation specialists and coordinators
- Transplant pharmacists
- Patients are very welcome to attend the Educational Stream on Day 1, 2 and 3 and will be invited to contribute to all consensus workstreams.

EMERGING STARS

- Participate in a comprehensive programme
- Attend the workshop and the plenary session when results are shared
- Network with colleagues and meet the experts
- Continue the mentoring experience

EXPERT PROFESSIONALS

- Follow and contribute to the pre-meeting discussion
- Attend the session where workshop results are shared
- Meet leaders and peers in small sessions
- Continue the mentoring experience

OPINION LEADERS

- Work on consensus building
- Report back on results
- Mentor learning professionals
- Coordinate dissemination of consensus
STRUCTURE

A 1-YEAR LONG JOURNEY

PRE-MEETING

- Pre-meeting discussion on Transplant Live
- Briefing of consensus workshop participants
- Communications
- Online education activities (evidence sharing, short update webinars)

CONSENSUS WORKSHOPS

Day 1
- End points
- CMV
- Cancer
- DCD
- NASH
- Desensitisation

Day 2
- Networking lunch
- Mentoring and learning sessions
- One-day scientific sessions (Topics to be defined by Sections & Committees)

Day 3

PLENARY SESSION

POST-MEETING

- Post-meeting discussion on Transplant Live
- Dissemination of consensus (publication on TI, social media, expert webinars on Transplant Live)
- Communications
AKNOWLEDGEMENTS

The Workstream "Transplanting Across Immunological Barriers" is possible thanks to the kind support of HANSA BIOPHARMA.

The Workstream "CMV infection and disease – the impact on transplanted patients" is possible thanks to the kind support of MSD.

TLJ 2.0 is kindly supported by astellas.

The Digital Outpatients Awards is supported by SANDOZ A Novartis Division.
ABOUT TLJ2018

MUNICH, GERMANY
6-10 NOVEMBER, 2018

MOST REPRESENTED COUNTRIES

456 PARTICIPANTS

% ATTENDEES PER EVENT

23 SUPPORTERS
#ESOTTLJ

Consensus workshops
Mentoring and learning sessions
Scientific sessions

Learning through Social Media Conversations #SoMe
ABOUT ESOT

The European Society for Organ Transplantation (ESOT) is the umbrella organisation under which all European transplant activities are organised.

ESOT cooperates with many other organisations to structure and streamline transplant activities in Europe. Several Sections and Committees within ESOT represent expert knowledge on the respective organs and specialty fields.

ESOT trains and supports its members through an extensive Educational Programme and encourages excellence through its Awards & Grants Programme.

Furthermore, ESOT gathers the European and international transplant scene at its biennial Congress.

TLJ 2.0 VENUE

Prague Congress Centre
5. května 1640/65
140 21 Praha 4
Nusle, Czech Republic

MEETING ORGANIZER

ESOT
Riviera dei Mugnai 8/24, 35131 Padova – Italy

Project Manager: Giovanna Rossi
giovanna.rossi@esot.org - +39 346 514 7493